Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/01.NURSE.0000459791.64593.ca | DOI Listing |
J Physiol
July 2024
Manaaki Manawa - The Centre for Heart Research, Department of Physiology, University of Auckland, Grafton, Auckland, New Zealand.
Physiol Rev
July 2024
Early Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, United States.
Glucagon's ability to promote hepatic glucose production has been known for over a century, with initial observations touting this hormone as a diabetogenic agent. However, glucagon receptor agonism [when balanced with an incretin, including glucagon-like peptide 1 (GLP-1) to dampen glucose excursions] is now being developed as a promising therapeutic target in the treatment of metabolic diseases, like metabolic dysfunction-associated steatotic disease/metabolic dysfunction-associated steatohepatitis (MASLD/MASH), and may also have benefit for obesity and chronic kidney disease. Conventionally regarded as the opposing tag-team partner of the anabolic mediator insulin, glucagon is gradually emerging as more than just a "catabolic hormone.
View Article and Find Full Text PDFHypertens Res
February 2023
Dialysis Unit, University of the Ryukyus Hospital, Nishihara, Japan.
Artif Life
January 2023
CNRS.
While interest in artificial neural networks (ANNs) has been renewed by the ubiquitous use of deep learning to solve high-dimensional problems, we are still far from general artificial intelligence. In this article, we address the problem of emergent cognitive capabilities and, more crucially, of their detection, by relying on co-evolving creatures with mutable morphology and neural structure. The former is implemented via both static and mobile structures whose shapes are controlled by cubic splines.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!